BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34048614)

  • 21. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine.
    Cyrenne BM; Al-Mohammedi F; DeKoven JG; Alhusayen R
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):e546-e548. PubMed ID: 33982814
    [No Abstract]   [Full Text] [Related]  

  • 22. Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases.
    Bostan E; Elmas L; Yel B; Yalici-Armagan B
    Dermatol Ther; 2021 Nov; 34(6):e15110. PubMed ID: 34427024
    [No Abstract]   [Full Text] [Related]  

  • 23. Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis.
    Ducloux D; Colladant M; Chabannes M; Yannaraki M; Courivaud C
    Kidney Int; 2021 Sep; 100(3):702-704. PubMed ID: 34216675
    [No Abstract]   [Full Text] [Related]  

  • 24. Viral-like Reaction or Hypersensitivity? Erythema Multiforme Minor Reaction and Moderate Eosinophilia After the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 Vaccine.
    de Las Vecillas L; López J; Morchón E; Rodriguez F; Drake M; Martino M
    J Investig Allergol Clin Immunol; 2021 Feb; 32(1):77-78. PubMed ID: 34588156
    [No Abstract]   [Full Text] [Related]  

  • 25. Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID-19 vaccine.
    Okan G; Vural P
    Dermatol Ther; 2022 Mar; 35(3):e15280. PubMed ID: 34931408
    [No Abstract]   [Full Text] [Related]  

  • 26. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
    Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older.
    Auster O; Finkel U; Dagan N; Barda N; Laufer A; Balicer RD; Ben-Shachar S
    JAMA Netw Open; 2022 Apr; 5(4):e227657. PubMed ID: 35435973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up: comment.
    Serraino C; Melchio R; Badinella Martini M; Gerbaudo L; Fenoglio L
    Intern Emerg Med; 2022 Jan; 17(1):311-312. PubMed ID: 35006536
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.
    Haller MC; Kaiser RA; Langthaler S; Brandstetter C; Apfalter P; Kerschner H; Cejka D
    Transpl Int; 2021; 35():10026. PubMed ID: 35185359
    [No Abstract]   [Full Text] [Related]  

  • 30. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
    Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
    JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-episodic angioedema with eosinophilia after BNT162b2 mRNA COVID-19 vaccination.
    Ishizuka K; Katayama K; Kaji Y; Tawara J; Ohira Y
    QJM; 2021 Dec; 114(10):745-746. PubMed ID: 34546346
    [No Abstract]   [Full Text] [Related]  

  • 32. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.
    Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O
    Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kounis syndrome associated with BNT162b2 mRNA COVID-19 vaccine presenting as ST-elevation acute myocardial infarction.
    Şancı E; Örçen C; Çelik OM; Özen MT; Bozyel S
    Anatol J Cardiol; 2022 Jan; 26(1):69-74. PubMed ID: 35191390
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis.
    Ionita C; Marcelli D; Nita C; Anton C; Berca S; Vacar S; Schiller O; Gheorghiu C; Barth C
    J Nephrol; 2022 Jan; 35(1):143-151. PubMed ID: 34978050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents.
    Van Praet JT; Vandecasteele S; De Roo A; De Vriese AS; Reynders M
    Clin Infect Dis; 2021 Dec; 73(11):2145-2147. PubMed ID: 33825869
    [No Abstract]   [Full Text] [Related]  

  • 36. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up-Reply.
    Ferrara P; Antonazzo IC; Polosa R
    Intern Emerg Med; 2022 Jan; 17(1):313-314. PubMed ID: 35006537
    [No Abstract]   [Full Text] [Related]  

  • 37. Herpes zoster viral infection after AZD1222 and BNT162b2 coronavirus disease 2019 mRNA vaccines: a case series.
    Koumaki D; Krueger-Krasagakis SE; Papadakis M; Katoulis A; Koumaki V; Evangelou G; Stefanidou M; Mylonakis D; Zografaki K; Krasagakis K
    J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):e85-e86. PubMed ID: 34606142
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
    Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
    Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response.
    Tychala A; Meletis G; Katsimpourlia E; Gkeka I; Dimitriadou R; Sidiropoulou E; Skoura L
    Hum Vaccin Immunother; 2021 Dec; 17(12):5148-5149. PubMed ID: 34714711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.